Please confirm that your email address is correct, so you can successfully receive this alert.
To the Editor: As a clinician, I was disappointed by the negative results reported by Prakash S. Masand, M.D., et al. (1) about sustained-released bupropion for the treatment of sexual dysfunction induced by selective serotonin reuptake inhibitors (SSRIs). However, while awaiting the results of larger studies using the higher doses of bupropion that these authors called for, we can take some consolation in the fact that this study was “supported in part by a grant from GlaxoSmithKline” (p. 807), the makers of sustained-released bupropion. At a time when there are concerns about the influence of the pharmaceutical industry on pharmacologic research and practice (2), it is nice to see that a study in which the company’s product did not fare well was published rather than having it end up in the proverbial file drawer.
Download citation file:
Web of Science® Times Cited: 1